12:00 AM
Feb 28, 2011
 |  BC Week In Review  |  Company News  |  Deals

Cell Signaling Technology, Astellas deal

Astellas and Cell Signaling Technology partnered to pool their respective IP covering the EML4-ALK oncogenic fusion protein. Astellas will have rights...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >